financetom
Business
financetom
/
Business
/
CoStar Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CoStar Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Apr 28, 2026 2:06 PM

04:42 PM EDT, 04/28/2026 (MT Newswires) -- CoStar ( CSGP ) reported Q1 adjusted earnings late Tuesday of $0.23 per diluted share, up from $0.15 a year earlier.

Analysts polled by FactSet expected $0.18.

Revenue for the three months ended March 31 was $897 million, up from $732 million a year earlier.

Analysts surveyed by FactSet expected $896.7 million.

For Q2, the company expects adjusted EPS of $0.27 to $0.30 on revenue of $922 million to $932 million. Analysts expect EPS of $0.27 on revenue of $929.4 million.

For the full-year 2026, the company now expects adjusted EPS of $1.32 to $1.39. It reiterated its revenue forecast of $3.78 billion to $3.82 billion. Analysts expect EPS of $1.30 on revenue of $3.81 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review. Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4...
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Oct 17, 2024
09:07 AM EDT, 10/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Thursday that it has completed recruitment for the first part of its early-stage trial for IMP761, a LAG-3 immunotherapy aimed at treating autoimmune diseases. The part A, single dose, of the placebo-controlled, double-blind trial reported no safety issues following drug administration, the company said. The trial will now...
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI and Bain are extending their partnership to sell OpenAI's ChatGPT and other AI tools to the consulting firm's clients, The Wall Street Journal reported Thursday. The companies started a sales partnership in 2023 and in August 13,000 Bain consultants got licenses for ChatGPT Enterprise, according to the...
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Oct 17, 2024
02:31 PM EDT, 10/17/2024 (MT Newswires) -- Greenheart Gold ( GHRTF ) on Thursday said it closed a brokered private placement financing that raised $36 million as it placed 72.09-million shares priced at $0.50 each. Proceeds will be used to acquire properties mineral properties in Guyana and Suriname, for working capital and general corporate purposes. Greenheart Gold ( GHRTF )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved